PDF herunterladen
Thorac Cardiovasc Surg 2013; 61(06): 470-478
DOI: 10.1055/s-0032-1331843
Original Thoracic
Georg Thieme Verlag KG Stuttgart · New York

Prognostic Scoring System Predictive of Survival after Surgical Resection of Esophageal Carcinoma

Ines Gockel
1   Department of General, Visceral and Transplant Surgery, University Medical Center of Mainz, Germany, Mainz, Germany
,
Stefan Niebisch
1   Department of General, Visceral and Transplant Surgery, University Medical Center of Mainz, Germany, Mainz, Germany
,
Lynetta K. Campbell
2   Department of Statistics, Texas A&M University, Houston, Texas, USA
,
George Sgourakis
3   Department of General Surgery and Surgical Oncology Unit of “Korgialenio—Benakio,” Red Cross Hospital, Athens, Greece
,
Theodor Junginger
1   Department of General, Visceral and Transplant Surgery, University Medical Center of Mainz, Germany, Mainz, Germany
› Institutsangaben
Weitere Informationen

Publikationsverlauf

29. Juli 2012

01. November 2012

Publikationsdatum:
08. März 2013 (online)

    Lizenzen und Reprints Alle Artikel dieser Rubrik

Abstract

Background The aim of our study was to develop a prognostic index score for patients undergoing surgical resection for esophageal cancer that accurately determines survival with specific clinicopathological characteristics.

Methods Clinical, histological, and demographical variables of 475 patients were entered in an univariate and multivariate regression model, followed by individual calculation of the Prognostic Indicator Score and model validation via simulation.

Results Significant variables included in the scoring system were number of positive lymph nodes, pT, pL, R, obesity, and American Society of Anesthesiologist classification. Survival probability and its associated hazard function was significantly different between the scores, with an increase of hazard ratio ranging from 2.56 (score 2) to 20 (score 6 or higher). Comparing histological cancer entities revealed statistical significance only between stage IIA versus IIB in squamous cell and stage IIIA versus IIIB in adenocarcinoma.

Conclusions According to our methodology, an individualized follow-up by each possible score might allow interdisciplinary selection of patients for treatments based on expected survival. This may represent a breakthrough in patient selection for currently available treatments and clinical studies.

Keywords

prognostic index score - esophageal cancer - surgical approach - operative - computing methodologies - model validation
 

  • References

  • 1 Brown LM, Devesa SS, Chow WH. Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age. J Natl Cancer Inst 2008; 100 (16) 1184-1187
    CrossrefPubMedGoogle Scholar
  • 2 Baba M, Aikou T, Natsugoe S , et al. Appraisal of ten-year survival following esophagectomy for carcinoma of the esophagus with emphasis on quality of life. World J Surg 1997; 21 (3) 282-285 , discussion 286
    CrossrefPubMedGoogle Scholar
  • 3 Gockel I, Gönner U, Domeyer M, Lang H, Junginger T. Long-term survivors of esophageal cancer: disease-specific quality of life, general health and complications. J Surg Oncol 2010; 102 (5) 516-522
    PubMedGoogle Scholar
  • 4 Wittekind C, Oberschmid B. Gastrointestinal tumors: new N classification of the UICC. Chirurg 2010; 81 (2) 95-98 , 100–102
    CrossrefPubMedGoogle Scholar
  • 5 Nomura M, Shitara K, Kodaira T , et al. Prognostic impact of the 6th and 7th American Joint Committee on Cancer TNM staging systems on esophageal cancer patients treated with chemoradiotherapy. Int J Radiat Oncol Biol Phys 2012; 82 (2) 946-952
    CrossrefPubMedGoogle Scholar
  • 6 Hayashi Y, Correa AM, Hofstetter WL , et al. The influence of high body mass index on the prognosis of patients with esophageal cancer after surgery as primary therapy. Cancer 2010; 116 (24) 5619-5627
    CrossrefPubMedGoogle Scholar
  • 7 von Rahden BH, Stein HJ, Feith M, Becker K, Siewert JR. Lymphatic vessel invasion as a prognostic factor in patients with primary resected adenocarcinomas of the esophagogastric junction. J Clin Oncol 2005; 23 (4) 874-879
    CrossrefPubMedGoogle Scholar
  • 8 Yu E, Tai P, Malthaner R , et al. What are the factors that predict outcome at relapse after previous esophagectomy and adjuvant therapy in high-risk esophageal cancer?. Curr Oncol 2010; 17 (6) 46-51
    PubMedGoogle Scholar
  • 9 Kim MK, Kim SB, Ahn JH , et al. Treatment outcome and recursive partitioning analysis-based prognostic factors in patients with esophageal squamous cell carcinoma receiving preoperative chemoradiotherapy. Int J Radiat Oncol Biol Phys 2008; 71 (3) 725-734
    CrossrefPubMedGoogle Scholar
  • 10 Yuequan J, Shifeng C, Bing Z. Prognostic factors and family history for survival of esophageal squamous cell carcinoma patients after surgery. Ann Thorac Surg 2010; 90 (3) 908-913
    CrossrefPubMedGoogle Scholar
  • 11 Gu Y, Swisher SG, Ajani JA , et al. The number of lymph nodes with metastasis predicts survival in patients with esophageal or esophagogastric junction adenocarcinoma who receive preoperative chemoradiation. Cancer 2006; 106 (5) 1017-1025
    CrossrefPubMedGoogle Scholar
  • 12 Rice TW, Blackstone EH, Rybicki LA , et al. Refining esophageal cancer staging. J Thorac Cardiovasc Surg 2003; 125 (5) 1103-1113
    CrossrefPubMedGoogle Scholar
  • 13 Xu QR, Zhuge XP, Zhang HL, Ping YM, Chen LQ. The N-classification for esophageal cancer staging: should it be based on number, distance, or extent of the lymph node metastasis?. World J Surg 2011; 35 (6) 1303-1310
    CrossrefPubMedGoogle Scholar
  • 14 Gu ZD, Shen LY, Wang H , et al. HOXA13 promotes cancer cell growth and predicts poor survival of patients with esophageal squamous cell carcinoma. Cancer Res 2009; 69 (12) 4969-4973
    CrossrefPubMedGoogle Scholar
  • 15 Gaur P, Sepesi B, Hofstetter WL , et al; M. D. Anderson Esophageal Cancer Group; University of Rochester School of Medicine and Dentistry Foregut Group. Endoscopic esophageal tumor length: a prognostic factor for patients with esophageal cancer. Cancer 2011; 117 (1) 63-69
    CrossrefPubMedGoogle Scholar
  • 16 Tuynman JB, Lagarde SM, Ten Kate FJ, Richel DJ, van Lanschot JJ. Met expression is an independent prognostic risk factor in patients with oesophageal adenocarcinoma. Br J Cancer 2008; 98 (6) 1102-1108
    CrossrefPubMedGoogle Scholar
  • 17 Li L, Zhao J, Wu Z, Wang G, Chen G. Meta-analysis: clinicopathological and prognostic significance of cyclooxygenase-2 expression on oesophageal squamous cell carcinoma. Aliment Pharmacol Ther 2009; 30 (6) 589-596
    CrossrefPubMedGoogle Scholar
  • 18 Tong DK, Law S, Kwong DL, Chan KW, Lam AK, Wong KH. Histological regression of squamous esophageal carcinoma assessed by percentage of residual viable cells after neoadjuvant chemoradiation is an important prognostic factor. Ann Surg Oncol 2010; 17 (8) 2184-2192
    CrossrefPubMedGoogle Scholar
  • 19 Zhou ZQ, Cao WH, Xie JJ , et al. Expression and prognostic significance of THBS1, Cyr61 and CTGF in esophageal squamous cell carcinoma. BMC Cancer 2009; 9: 291
    CrossrefPubMedGoogle Scholar
  • 20 Xie JJ, Xu LY, Wu ZY , et al. Prognostic implication of ezrin expression in esophageal squamous cell carcinoma. J Surg Oncol 2011; 104 (5) 538-543 [Epub ahead of print]
    CrossrefPubMedGoogle Scholar
  • 21 Motoyama S, Miura M, Hinai Y , et al. Interleukin-2 -330T > G genetic polymorphism associates with prognosis following surgery for thoracic esophageal squamous cell cancer. Ann Surg Oncol 2011; 18 (7) 1995-2002 [Epub ahead of print]
    CrossrefPubMedGoogle Scholar
  • 22 Tsuchikawa T, Ikeda H, Cho Y , et al. Association of CD8+ T cell infiltration in oesophageal carcinoma lesions with human leucocyte antigen (HLA) class I antigen expression and survival. Clin Exp Immunol 2011; 164 (1) 50-56
    PubMedGoogle Scholar
  • 23 Greenstein AJ, Litle VR, Swanson SJ , et al. Effect of the number of lymph nodes sampled on postoperative survival of lymph node-negative esophageal cancer. Cancer 2008; 112 (6) 1239-1246
    CrossrefPubMedGoogle Scholar
  • 24 Cunningham D, Allum WH, Stenning SP , et al. MAGIC Trial Participants. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355 (1) 11-20
    CrossrefPubMedGoogle Scholar
  • 25 Brücher BL, Becker K, Lordick F , et al. The clinical impact of histopathologic response assessment by residual tumor cell quantification in esophageal squamous cell carcinomas. Cancer 2006; 106 (10) 2119-2127
    CrossrefPubMedGoogle Scholar
  • 26 Langer R, Ott K, Feith M , et al. Prognostic significance of histopathological tumor regression after neoadjuvant chemotherapy in esophageal adenocarcinomas. Mod Pathol 2009; 22 (12) 1555-1563
    CrossrefPubMedGoogle Scholar